Flossbach Von Storch SE Boosts Stake in Thermo Fisher Scientific Inc. (NYSE:TMO)

Flossbach Von Storch SE lifted its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 5.8% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,412,839 shares of the medical research company's stock after acquiring an additional 77,554 shares during the quarter. Thermo Fisher Scientific accounts for 3.0% of Flossbach Von Storch SE's portfolio, making the stock its 15th largest position. Flossbach Von Storch SE owned about 0.37% of Thermo Fisher Scientific worth $703,029,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Brighton Jones LLC lifted its stake in shares of Thermo Fisher Scientific by 28.9% in the 4th quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company's stock valued at $2,293,000 after purchasing an additional 988 shares during the period. Revolve Wealth Partners LLC grew its holdings in shares of Thermo Fisher Scientific by 4.2% in the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock valued at $255,000 after purchasing an additional 20 shares during the period. Bank Pictet & Cie Europe AG boosted its stake in Thermo Fisher Scientific by 0.3% during the fourth quarter. Bank Pictet & Cie Europe AG now owns 153,157 shares of the medical research company's stock worth $79,677,000 after buying an additional 461 shares during the period. Proficio Capital Partners LLC boosted its stake in Thermo Fisher Scientific by 32.1% during the fourth quarter. Proficio Capital Partners LLC now owns 1,466 shares of the medical research company's stock worth $763,000 after buying an additional 356 shares during the period. Finally, Moran Wealth Management LLC lifted its position in shares of Thermo Fisher Scientific by 2.4% during the fourth quarter. Moran Wealth Management LLC now owns 1,089 shares of the medical research company's stock worth $567,000 after purchasing an additional 26 shares in the last quarter. Institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific Price Performance

Shares of TMO traded up $12.36 during midday trading on Thursday, hitting $432.24. The company's stock had a trading volume of 1,252,680 shares, compared to its average volume of 2,394,045. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $627.88. The company's fifty day simple moving average is $408.93 and its two-hundred day simple moving average is $477.89. The company has a quick ratio of 1.38, a current ratio of 1.77 and a debt-to-equity ratio of 0.64. The stock has a market capitalization of $163.17 billion, a price-to-earnings ratio of 25.35, a price-to-earnings-growth ratio of 2.27 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.10 by $0.05. Thermo Fisher Scientific had a return on equity of 17.15% and a net margin of 15.19%. The company had revenue of $10.36 billion for the quarter, compared to the consensus estimate of $10.23 billion. During the same period in the previous year, the business earned $5.11 EPS. The firm's revenue was up .2% compared to the same quarter last year. As a group, equities analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 15th. Shareholders of record on Friday, June 13th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 0.40%. The ex-dividend date is Friday, June 13th. Thermo Fisher Scientific's dividend payout ratio (DPR) is 10.09%.

Insider Activity

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction dated Monday, April 28th. The stock was sold at an average price of $429.93, for a total transaction of $128,979.00. Following the completion of the sale, the executive vice president owned 23,167 shares of the company's stock, valued at $9,960,188.31. The trade was a 1.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.33% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the stock. UBS Group cut shares of Thermo Fisher Scientific from a "buy" rating to a "neutral" rating and reduced their target price for the company from $500.00 to $460.00 in a report on Tuesday. The Goldman Sachs Group set a $610.00 target price on shares of Thermo Fisher Scientific and gave the stock a "buy" rating in a research report on Wednesday, April 23rd. Royal Bank Of Canada lowered their price objective on shares of Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating on the stock in a research report on Thursday, April 24th. Wall Street Zen raised Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a report on Wednesday, May 21st. Finally, Scotiabank cut their target price on shares of Thermo Fisher Scientific from $650.00 to $605.00 and set a "sector perform" rating for the company in a research report on Friday, April 25th. Five analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $601.05.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.